The document discusses Israel's National Health Basket (NHB), which determines public funding for new drugs and medical technologies each year. A budget of around 300 million NIS is allocated annually for the NHB, but drugs and technologies worth around 2 billion NIS are submitted for inclusion. The NHB Committee aims to select submissions that provide maximum public health benefits within the budget. Companies submitting products must provide dossiers demonstrating clinical benefits, budget impacts, and cost-effectiveness to justify inclusion. The consulting services described help companies navigate this national reimbursement process and maximize their prospects of NHB inclusion.

1. Background
The National Health Basket (NHB), defined by the National Health Insurance Law, is
the main channel through which new drugs and medical technologies become
available to the public via national funding in Israel. New drugs are added to the NHB
in a yearly process to which special budget is allocated by the government. This
budget changes from year to year, in the last several years its magnitude was 300M
NIS. Each year, drugs and technologies worth of about 2B NIS are submitted for
NHB inclusion, thus compete on the allocated budget.
The NHB Committee’s duty is to recommend on the NHB inclusion of those drugs
and technologies that would maximize public’s benefit within the framework of the
predetermined budget. Thus, Ministry of Health and the Committee are looking for
the best methodology to prioritize the drugs and technologies submitted, in order to
achieve this objective.
Pharmaceutical and Medical Devices companies submitting their products for
inclusion in the NHB, have to build a comprehensive and convincing dossier for the
reimbursement authorities that would include detailed information on the clinical
benefit of the drug, present a reasonable budget-impact analysis and convince NHB
Committee that the drug’s cost-effectiveness ratio justifies its preference over other
submitted drugs and that its inclusion in the NHB would meet the objective of
maximizing public’s health. If the NHB Committee members and other key decision
makers are convinced of that, then they will prioritize the submitted drug higher than
other submitted drugs, which will in turn increase its chances for NHB inclusion.
Strategic Consulting Services - National Health Basket & Market Access
We provide the following services for pharmaceutical and Medical Technology
companies:
Comprehensive strategic consultancy service in the field of national reimbursement
processes: NHB coverage, sick-funds formularies, complementary insurances and
hospital formularies coverage of new medications and medical devices.
Leading reimbursement processes for specific products. Setting detailed workplans
containing all the elements required to maximize the prospects of NHB inclusion
and/or inclusion in the sick-funds or hospital formularies.
Preparation of NHB submission dossiers.
Performing and adapting economic analyses required by the authorities: budget
impact and cost-effectiveness analyses (where required).

2. Planning and supporting company's activities vis-a-vis the authorities and relevant
influencers: Ministry of Health, sick-funds, medical associations, NHB Committee and
economic sub-committee members etc.
Representation of the Company before relevant authorities: the Ministry of Health,
sick funds and NHB Committee members.
Managing continuous contacts with key decision makers, delivering messages that
would leverage their support in NHB/sick-funds/hospital formularies inclusion of the
Company products.
Consultation services on local pricing strategy, as part of the local penetration
strategy.
Consultation services in the field of business development.